Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada.
Division of Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada.
Drug Saf. 2017 Nov;40(11):1119-1129. doi: 10.1007/s40264-017-0555-9.
Prospective pharmacovigilance aims to rapidly detect safety concerns related to medical products. The exposure model selected for pharmacovigilance impacts the timeliness of signal detection. However, in most real-life pharmacovigilance studies, little is known about which model correctly represents the association and there is no evidence to guide the selection of an exposure model. Different exposure models reflect different aspects of exposure history, and their relevance varies across studies. Therefore, one potential solution is to apply several alternative exposure models simultaneously, with each model assuming a different exposure-risk association, and then combine the model results.
We simulated alternative clinically plausible associations between time-varying drug exposure and the hazard of an adverse event. Prospective surveillance was conducted on the simulated data by estimating parametric and semi-parametric exposure-risk models at multiple times during follow-up. For each model separately, and using combined evidence from different subsets of models, we compared the time to signal detection.
Timely detection across the simulated associations was obtained by fitting a set of pharmacovigilance models. This set included alternative parametric models that assumed different exposure-risk associations and flexible models that made no assumptions regarding the form/shape of the association. Times to detection generated using a simple combination of evidence from multiple models were comparable to those observed under the ideal, but unrealistic, scenario where pharmacovigilance relied on the single 'true' model used for data generation.
Simulation results indicate that, if the true model is not known, an association can be detected in a more timely manner by first fitting a carefully selected set of exposure-risk models and then generating a signal as soon as any of the models considered yields a test statistic value below a predetermined testing threshold.
前瞻性药物警戒旨在快速检测与医疗产品相关的安全问题。用于药物警戒的暴露模型选择会影响信号检测的及时性。然而,在大多数现实生活中的药物警戒研究中,对于哪种模型能正确代表关联知之甚少,也没有证据来指导暴露模型的选择。不同的暴露模型反映了暴露史的不同方面,其相关性因研究而异。因此,一种潜在的解决方案是同时应用几种替代的暴露模型,每个模型都假设了不同的暴露风险关联,然后结合模型结果。
我们模拟了时间变化的药物暴露与不良事件风险之间的几种替代临床合理关联。通过在随访期间的多个时间点估计参数和半参数暴露风险模型,对模拟数据进行前瞻性监测。对于每个单独的模型,并使用不同模型子集的综合证据,我们比较了信号检测的时间。
通过拟合一组药物警戒模型,及时检测到了模拟关联中的信号。该组模型包括假设不同暴露风险关联的替代参数模型和不假设关联形式/形状的灵活模型。使用来自多个模型的证据进行简单组合生成的检测时间与在理想但不现实的情况下观察到的检测时间相当,在这种情况下,药物警戒仅依赖于用于数据生成的单个“真实”模型。
模拟结果表明,如果不知道真实模型,可以通过首先拟合一组经过精心选择的暴露风险模型,然后一旦任何考虑的模型产生低于预定测试阈值的测试统计值,就生成信号,更及时地检测到关联。